Arbutus Biopharma (ABUS) Fundamental Analysis: Revenue, Earnings & Valuation

4.07 / 10

Netural

Fundamental rating is Neutral (4.1/10). Revenue‑MV and Profit‑MV are positive, while Current assets turnover and Income‑tax‑to‑profit are weak. Asset‑MV is low. Overall, the balance sheet shows modest strength with notable efficiency gaps.

Analysis Checks(7/10)

Revenue-MV

Value-5.48

Score2/3

Weight23.30%

1M Return8.05%

Inventory turnover ratio

Value47.57

Score3/3

Weight20.16%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.27%

1M Return1.67%

Profit-MV

Value0.41

Score2/3

Weight18.96%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.47%

1M Return0.21%

Current assets turnover ratio

Value0.12

Score0/3

Weight-3.54%

1M Return-1.61%

Fixed assets turnover ratio

Value7.56

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight10.02%

1M Return4.08%

Asset-MV

Value-0.48

Score0/3

Weight7.78%

1M Return2.73%

Cash-MV

Value-0.09

Score2/3

Weight18.57%

1M Return6.19%

Is ABUS undervalued or overvalued?

ABUS scores 4.07/10 on fundamentals and holds a Fair valuation at present. Backed by its -38.52% ROE, -237.88% net margin, -26.29 P/E ratio, 11.50 P/B ratio, and 55.26% earnings growth, these metrics solidify its Netural investment rating.